Lorlatinib in ALK- and ROS1-positive NSCLC: The future has a start

Francesco Facchinetti, Luc Friboulet

Résultats de recherche: Contribution à un journal › Editorial

7 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	S103-S106
journal	Translational Lung Cancer Research
Volume	7
Les DOIs	https://doi.org/10.21037/tlcr.2018.02.04
état	Publié - 1 avr. 2018

Accès au document

@article{744ba458586944f5a620a1091355a643,

title = "Lorlatinib in ALK- and ROS1-positive NSCLC: The future has a start",

author = "Francesco Facchinetti and Luc Friboulet",

year = "2018",

month = apr,

day = "1",

doi = "10.21037/tlcr.2018.02.04",

language = "English",

volume = "7",

pages = "S103--S106",

journal = "Translational Lung Cancer Research",

issn = "2218-6751",

}

TY - JOUR

T1 - Lorlatinib in ALK- and ROS1-positive NSCLC

T2 - The future has a start

AU - Facchinetti, Francesco

AU - Friboulet, Luc

PY - 2018/4/1

Y1 - 2018/4/1

UR - http://www.scopus.com/inward/record.url?scp=85045907368&partnerID=8YFLogxK

U2 - 10.21037/tlcr.2018.02.04

DO - 10.21037/tlcr.2018.02.04

M3 - Editorial

AN - SCOPUS:85045907368

SN - 2218-6751

VL - 7

SP - S103-S106

JO - Translational Lung Cancer Research

JF - Translational Lung Cancer Research

ER -